Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, announced an $830 million growth equity round at a post-money valuation of $7.83 billion.

With this investment, Caris has raised approximately $1.3 billion in external financing since 2018. This financing represents one of the largest capital raises in precision medicine and includes a diverse syndicate of leading investors.

The round was led by Sixth Street, a leading global investment firm making its third investment in Caris since 2018. Funds and accounts advised by T. Rowe Price Associates, Inc., Silver Lake, Fidelity Management & Research Company LLC, and Coatue were significant participants in the round. Additional investors included Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corporation, Eaton Vance Equity (Morgan Stanley), Pura Vida Investments and First Light Asset Management. All existing investors from the 2020 financing participated in this deal along with a number of new investors.

The Caris Molecular Intelligence approach allows oncologists to assess all 22,000 genes in both DNA and RNA, utilizing whole exome sequencing, whole transcriptome sequencing, protein analysis, and proprietary AI models and signatures. This powerful combination delivers the most comprehensive and clinically relevant profiling available on the market.

As demand for personalized cancer care is expanding worldwide, patients and physicians seek to better understand their specific cancers to develop customized treatment plans that ultimately lead to better outcomes. This financing provides Caris with strategic capital for continued commercial expansion and investment toward delivering a first-in-class liquid biopsy platform with high concordance to tissue across different modalities including therapy selection, recurrence monitoring and early screening across all cancer types.

“Caris puts the patient at the center of everything we do. This recent raise will help us bring our market-leading science and technologies to as many patients as possible, ultimately reinventing cancer care,” said David D. Halbert, Chairman and CEO of Caris Life Sciences. “We plan to unlock the full potential of precision medicine through comprehensive interrogation of cancer at the molecular level.  This will allow the delivery of transformative applications of molecular science, including the launch of our early detection (stage 1 and stage 2) blood-based pan-cancer test, providing results for every patient with no non-shedders.”

This financing represents the third notable investment by Sixth Street in support of Caris’ vision and growth. In 2018, Sixth Street invested $150 million in the form of growth debt. In 2020, Sixth Street participated in the $235 million equity raise and invested an additional $75 million in growth debt financing. With commercial and research progress that demonstrated future growth potential, Sixth Street led this round with a significant equity commitment.

“Since our original investment in 2018, Caris has steadily advanced its position as the market-leading precision medicine company by continuing to advance innovative product development and pursuing new initiatives in blood-based molecular science profiling, while expanding the application of its artificial intelligence platform,” said Vijay Mohan, Co-founding Partner at Sixth Street and Caris Board Member. “We are proud to continue to support Caris’ growth, as we believe Caris is the highest-quality platform in this revolutionary sector.”

“The strong participation of all our existing, as well as new investors, is a testament to the promise of the Caris platform and supports our leading position as the most innovative company in the precision medicine space,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “We are very appreciative of the high quality and diversity of this syndicate of investors which includes leading mutual funds, healthcare specialist funds, technology-focused funds, sovereign wealth and pension funds and family offices.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine